Abstract
BackgroundDifferent than for rheumatoid arthritis, the potential benefits of conventional synthetic disease modifying drug (csDMARD) co-medication among psoriatic arthritis (PsA) patients receiving tumor necrosis factor inhibitors (TNFi) remain unclear.1ObjectivesThis study...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
